Bristol Myers Squibb (BMS), a leading biopharmaceutical company with a dominant position in immuno-oncology, held a press conference in Cyprus on April 29, 2025, where eminent pathologists-oncologists discussed the importance of harnessing innovative immuno-oncology therapies to improve the care of oncology patients and the importance of ensuring their timely access to innovative treatments. The event was moderated by Eleni Demetriou, Director of the Oncology Department of BMS Greece and Cyprus.
